Session Details

Session Details

03:45 PM - 05:30 PM - Ballroom 3

Liujiang Song - PhD - Asklepios BioPharmaceutical, Inc.

Co-Chair

03:45 PM - 04:00 PM - Ballroom 3

Vijesh Kumar - PhD - Spark Therapeutics

289: Optimizing for > 95 % rAAV Empty Capsid Removal at Process Scale with Anion Exchange Chromatography Using a Mechanistic Model

03:45 PM - 05:30 PM - Ballroom 3

Chao Huang - Ultragenyx

Co-Chair

04:00 PM - 04:15 PM - Ballroom 3

Matt Edwards - Affinia Therapeutics

290: A Proprietary HEK293 AAV Production System Can Achieve Greater Than 50% Full Capsids with Greater Than 1e15vg/L at Harvest Enabling Scalable Chromatography-Based Polishing with High Yield and Purity

04:15 PM - 04:30 PM - Ballroom 3

Thomas Thiers - Oxford Biomedica (US) LLC

291: Identification and Control of AAV Charge Heterogeneity through Optimized Bioreactor Operation

04:30 PM - 04:45 PM - Ballroom 3

Jiten Doshi - PhD - Mass Eye and Ear Infirmary

292: Next Generation Adeno Helper Plasmids and Helper Stable Cell Lines for Efficient AAV Vector Production

04:45 PM - 05:00 PM - Ballroom 3

Érica Schulze - PhD. - Sartorius Stedim Biotech GmbH

293: Development of a Powerful AAV Production Platform by Leveraging Comprehensive Design-of-Experiment & High-Throughput Automated Bioreactors

05:00 PM - 05:15 PM - Ballroom 3

Mikako Wada - PhD - Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo

294: Short-Term and Large-Scale Production of High-Quality Recombinant Adeno-Associated Virus Using a Zonal Ultracentrifugation

05:15 PM - 05:30 PM - Ballroom 3

Stefan Seeber - PhD - Roche Diagnostics GmbH

295: Generation of a Stable High-Titer Production Cell Line for Therapeutic AAV Vectors